OBJECTIVES: Heterotopic heart transplantation (HHTx) is a therapeutic option in heart failure patients with fixed elevated pulmonary hypertension. However, survival is poorer in HHTx recipients, and with improving results in continuous flow ventricular assist devices (VADs), many patients can be bridged to allow normalization of pulmonary artery pressures, making them orthotopic heart transplant (OHTx) candidates. Thus, the aim of this study was to analyse the survival of our HHTx cohort and compare them with our VAD bridge patients.
INTRODUCTION
When the first heterotopic heart transplantion (HHTx) was described in 1974, the main objective was to provide left ventricular support to the heart failure patient, but leave the native heart in situ to provide assistance during periods of rejection of the transplanted heart [1] . With the advent of Cyclosporine A in 1984, this option was no longer required, and given that the HHTx was a more challenging operative procedure, it quickly became superseded. In the 1990s, we revisited the HHTx option for a number of reasons [2] . Donor numbers in Australia at that time were very low at only 9 per million population, our waiting list was filled with heavier patients (>80 kg), and many of our waiting list patients had high pulmonary pressures. With the previously documented under-utilization of smaller cardiac allografts [3] and marginal allografts, and the predictably long ischaemic times in Australia [4] , we decided to revisit the HHTx option in an attempt to increase the utilization of available organs and to improve waiting list times for these high-risk patients. However, in the last decade, utilization of the heterotopic heart transplant option has waned in our hospital. One of the reasons is the poorer survival identified in HHTx recipients [2] . We also felt that the improved results of continuous flow ventricular assist devices (VADs) meant that many of these patients could be bridged to allow normalization of pulmonary artery pressures, and reduction of their weight, thus making them orthotopic heart transplant (OHTx) candidates.
Therefore, the aim of this study was to critically analyse the role of HHTx in the continuous flow VAD era.
PATIENTS AND METHODS
A retrospective chart review of prospectively collected data on all patients who underwent cardiac transplantation and/or left VAD (LVAD) implantation as a bridge to transplantation at our institution between July 1997 and March 2012 was performed. During this time, 359 heart transplants were undertaken. Of these,concomitant lung transplant, leaving 342 heart transplant patients to be analysed. Over this same period, 162 VADs were implanted. Of those, 124 patients implanted as bridge to transplant are included in this analysis. Data on donor and recipient demographics, type and duration of VAD support, pre-and post-VAD pulmonary pressures, outcomes and survival were collected. Survival data were censored on 1 May 2012. Institutional ethics approval was granted for this study and individual patient consent was waived.
The HHTx were performed as a left-sided assist configuration, previously described elsewhere [1, 3] . Donor organ preservation consisted of 2000 ml of St Thomas' solution. Patients received standard triple immunosuppression therapy following cardiac transplantation, which includes methylprednisolone, cyclosporin and mycophenolate mofetil. Antithymocyte globulin or anti-interleukin-2 receptor antibody (Simulect) was also used where poor renal function or other drug side-effects mandated the use of lower doses of cyclosporin.
Patients listed for transplant in our institution are also considered for suitability for HHTx at the time of listing. In general, they tend to be older patients who are considered unsuitable for VAD implantation or those with high pulmonary artery pressures. Thus, these patients are allowed for both OHTx and HHTx when they go onto the waiting list. Allografts considered suitable for HHTx are generally from donors too small for any orthotopic recipient on our list, considered marginal for some other reason, or are anticipated to have a longer ischaemic time (of the order of 6 h) [2, 4] .
Statistical analysis
All analysis was conducted using STATA 11 (Statacorp, TX, USA) and SAS version 9.2 (SAS Institute, Inc., Cary, NC, USA). Normally distributed data are presented as mean and standard deviation (SD), and non-normally distributed data are presented as median and interquartile range (IQR). Univariate comparisons were performed using chi-square tests (or Fisher's exact tests where numbers were small), Student's unpaired t-tests for normally distributed variables ( paired t-tests for repeated measures in the same individuals) and Wilcoxon rank sum tests for non-normally distributed data. Actuarial survival of patients was presented using Kaplan-Meier curves with P-values calculated using log-rank tests. Univariate and multivariate analyses of survival were performed using Cox proportional hazards regression, with multivariate models developed using both stepwise selection and backwards elimination techniques before undergoing a final assessment for clinical and biological plausibility. All variables were considered for model inclusion (listed in Tables 1 and 2 and including date of transplant). Results are presented as hazard ratio (HR) and 95% confidence interval (CI). A two-sided P-value of 0.05 was considered to be statistically significant and used as the inclusion criteria for multivariate models.
RESULTS
Of the 342 heart transplants analysed, there were 315 OHTx and 27 HHTx. The demographics of these two groups are outlined in Table 1 . Median follow-up time for the entire group was 70 (range 0-180) months.
Indication for HHTx in the group of 27 patients was high pulmonary artery pressures in 23 patients (systolic pulmonary artery pressure 64.9 ± 8.8 mmHg [mean ± SD], a transpulmonary gradient of 17.3 ± 4.5 mmHg [mean ± SD] and pulmonary vascular resistance of 4.2 ± 1.9 Woods units [mean ± SD]). The other 4 patients received marginal donor organs with ischaemic times in excess of 6 h.
A total of 124 patients were implanted with an LVAD over the time frame of this review, with the intention of bridge to transplant. Eighteen of the 124 received the VAD as a bridge to candidacy, 15 of whom had prohibitively high pulmonary artery pressures and 3 of whom were treated with extracorporeal membrane oxygenation for cardiogenic shock prior to receiving a VAD. Of the 124, 69 have received an OHTx (and are included in the OHTx cohort in Table 1 ). Eight of the 69 had received the VAD for high pulmonary artery pressures as outlined above. We generally do not list the patient for transplantation after receiving a VAD for high pulmonary artery pressures for a minimum of 3 months and usually wait 6 months for pulmonary pressures to reduce satisfactorily.
Of the remaining 55 patients, 40 died or were delisted due to deteriorating medical condition, prior to transplantation. Fifteen patients currently remain active on the transplant waiting list. The Continuous normally distributed data presented as mean ± SD.
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demographics of the VAD cohort are outlined in Table 2 . The pulsatile VADs used were the Thoratec paracorporeal VAD (Thoratec, Pleasanton, USA) (n = 55) and the Novacor (WorldHeart, Salt Lake City, USA) (n = 10), and the continuous devices used were the Ventrassist (Ventracor, Sydney, Australia) (n = 52), Heartware HVAD (HeartWare, Framingham, USA) (n = 5) and the Heartmate II (Thoratec) (n = 2). Of the 69 patients who have been transplanted from a VAD, 25 (all with continuous flow devices) had complete pre-VAD and pretransplant right heart catheterization data that could be retrieved. Significant reductions are seen in pulmonary artery pressures comparing pre-VAD and post-VAD (pretransplant) data (Table 3) .
Survival of the groups was analysed with univariate analysis outlined in Table 4 . As can be seen, increasing donor age significantly reduced survival, as did HHTx. Both of these factors remained significant on multivariate analysis (and were the only significant variables) analysed as a fixed model against the OHTx group [donor age HR (95% CI) 1.03 (1.01-1.05), P = 0.003; HHTx vs OHTx 2.26 (1.25-4.09), P = 0.007]. Figure 1 compares the OHTx cohort with the HHTx cohort with the successful bridge-to-transplant patients in the OHTx cohort plotted separately. As can be seen from pairwise comparisons, there is no significant difference in survival between the patients who were successfully bridged to transplant and those who went straight to OHTx (P = 0.86). In comparison, the HHTx cohort has a significantly poorer survival when compared with either the bridge group (P = 0.009) or the OHTx group (P = 0.009). In Figure 2 , all bridged patients are included (that is, those who died on the device as well as those still waiting), and the pulsatile and continuous flow devices are plotted separately. As can be seen, there are significant differences between groups, with the continuous flow device group approaching the survival of the OHTx group. The pulsatile device bridge group demonstrates the worst survival, particularly in the first 90 days (P < 0.001). Between 2004 and 2009, both pulsatile and continuous VADs were implanted at our institution. Comparison of the survivals in this historically comparable cohort of 20 patients was done and was not statistically significant (P = 0.67).
DISCUSSION
In this retrospective analysis of 27 HHTx patients, we have noted significant differences in the OHTx and HHTx cohorts as expected. The HHTx recipients were significantly older, as were the donor organs they received. The donor allografts utilized in the HHTx cohort were significantly smaller than those used in the OHTx cohort, with longer ischaemic times. However, despite this, multivariate analysis still showed a detrimental effect of HHTx on survival.
Comparison of the two types of VADs implanted also showed significant differences with the continuous flow device group, demonstrating a significantly longer time supported on the device with significantly fewer deaths. The poorer survival in the pulsatile VAD group, particularly in the first 90 days, is likely attributable to the effect of era. Improvements in postoperative management and particularly intensive care in the last decade are likely to contribute to the similar survivals seen in the historically comparable subgroups of pulsatile and continuous flow devices.
We have shown superior survival in OHTx, compared with HHTx, recipients, which has been previously described [2] . We have also shown that bridging patients with continuous flow devices produces survival rates comparable to OHTx and better than HHTx. The results also show much poorer survival with pulsatile VADs, which has also been shown previously [5] . The results of this review bring into question the place of HHTx in the current era of mechanical device support.
HHTx has been considered in two main subsets of patients with New York Heart Association (NYHA) Class 4 heart failure. The first group consists of those patients for whom a donor heart would be insufficient to provide independent circulatory support, but could act in parallel to support a severely impaired native heart. The most common examples of this are donorrecipient size mismatch or utilization of a marginal donor allograft. By finding a way to utilize either under-sized or marginal organs, HHTx effectively widens the donor pool. This is of particular relevance for patients where a suitably sized donor is difficult to find, thus increasing the expected waiting list time for that potential recipient.
The more common indication for HHTx is fixed, elevated pulmonary vascular resistance refractory to medical management. In this group of patients, OHTx is contraindicated because of the high risk of postoperative right heart failure in a donor allograft unconditioned to high pulmonary pressures [6] . Until recent years, options for the treatment of pulmonary hypertension in patients with heart failure have been limited. Response to medical therapy was variable and often limited by systemic hypotension. In addition, the most effective therapy, epoprostenol ( prostacyclin), was only available by continuous intravenous infusion. Newer medical therapies have been able to produce significant improvements in pulmonary haemodynamics in patients with severe pulmonary hypertension to a point at which many of these patients become transplant candidates [7] . In patients with NYHA Class 4 heart failure and pulmonary hypertension, sildenafil and bosentan are current popular agents. Both these treatments are orally bioavailable and can be administered on an outpatient basis with relatively low side-effect profiles.
Despite the advances in the medical management of pulmonary hypertension, in some cases severe pulmonary hypertension may be refractory to even these newer agents, or these agents may be contraindicated due to systemic hypotension. In these cases, treatment options include either HHTx or bridging to OHTx with mechanical circulatory support devices.
There is a substantial body of evidence showing that pulsatile LVADs dramatically reduce pulmonary vascular resistance in the immediate period after insertion as well as in the long term [8] . However, pulsatile LVADs are associated with significant rates of mortality and morbidity. The REMATCH trial showed patients supported with pulsatile LVADs had 1-and 2-year survivals of 52 and 23%, respectively [9] . Larger patients with pulmonary hypertension might require LVAD support for a significant period of time awaiting a suitably size matched donor. A prolonged wait for a suitable donor on a pulsatile LVAD followed by OHTx arguably offers a higher risk of mortality and morbidity than a relatively prompt HHTx.
In recent years, mechanical circulatory support systems have improved markedly and there has been a shift towards using continuous flow devices. Recently, a randomized controlled trial spanning 38 US centres compared the outcomes of pulsatile and continuous LVADs. The primary end point was survival at 2 years, stroke-free, without reoperation. This was reached by 46% of patients with continuous LVADs and 11% with pulsatile LVADs. Actuarial survival estimates showed 1-and 2-year survival rates of 68 and 58%, respectively, in patients managed with continuous LVADs and 55 and 24% in patients managed with pulsatile LVADs [5] . The continuous LVADs were also associated with fewer adverse events and were more mechanically durable. Other studies have 
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shown benefits of continuous flow LVADs on pulmonary haemodynamics and right ventricular size [10, 11] .
The recent improvement in LVAD technology has prompted us to re-examine the utility of HHTx and question whether there is a role for this procedure in the future. Results from our series show that the survival of patients on newer continuous devices not only exceeds that of those on pulsatile devices, but also exceeds that of patients managed with HHTx. This suggests that while HHTx may have been a useful option for certain patients in the past, now that LVAD technology has improved so dramatically, patients may be better managed by continuous LVAD as a bridge to OHTx or as destination therapy ( provided right ventricular function is adequate). Perhaps, the only remaining roles for HHTx are in cases of significantly oversized recipients where no other options exist, or in older patients who are considered incapable of coping with a VAD.
Another consideration is the cost of these two treatment options. A recent cost analysis from the USA found that the cost of the index procedure hospitalization for OHTx in 2009 was $US168 576, and for VAD it was $208 522 [12] . The cost for a HHTx is likely to be more than OHTx, as we found that this group of older recipients tend to stay in the hospital longer (data not presented). However, this will still cost a lot less that a VAD implant followed by a transplant operation. Given the significant difference in survival between the two treatment options, it is possible that the increased cost of a VAD implant followed by a transplant is justified by the improved quality-adjusted life years afforded by that treatment algorithm. A detailed cost analysis was, however, beyond the scope of this study.
Being a retrospective study, there are limitations that can only be partially addressed by statistical techniques. Over the 15-year time frame of this study, it is likely that a shift in preferred treatment options would occur to some degree. Although we have tried to take this into account by analysing the transplant date as a variable, it is possible and likely that subtle shifts in practice cannot be adequately quantified mathematically. The repeated right heart catheterization data in only 25 of 69 successfully bridged patients are also a limitation. Only 39 of the 69 patients had pre-VAD data available on our database and these patients were spread over the latter 12 years of the 15-year review. In general, we do not repeat the right heart study if the patient had normal pulmonary artery pressures on the first study. Further, those patients who deteriorated quickly, requiring urgent VAD implantation, or in more recent years extracorporeal membrane oxygenation as a bridge to VAD, did not have the opportunity to have a formal right heart study pre-VAD implant.
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